May 12, 2022

Optometry Times
May 12, 2022

Alex Delaney-Gesing, Senior Editor

Companies are entering an exclusive licensing agreement for the development and commercialization of Brimochol PF and Carbachol PF in three new regions: Greater China, South Korea, and select Southeast Asian territories.

Visus Therapeutics and Zhaoke Ophthalmology Limited (ZKO) are entering an exclusive licensing agreement for the development and commercialization of Brimochol PF and Carbachol PF in three new regions: Greater China, South Korea, and select Southeast Asian territories.

Print